source
- Tessera Therapeutics reports infusion gene edit corrects 85% of blood cells in sickle cell studyTessera Therapeutics announced new data from its in-vivo gene editing program targeting sickle cell disease. The experimental therapy is given as a simple infusion, avoiding the complex cell engin…
- Podcast Highlights Community Oncology’s Growing Role in U.S. Cancer CareA new sponsored podcast episode explores how community oncology clinics are becoming a vital part of the U.S. cancer‑care landscape. The program, released in May 2026, discusses why these local cen…